Status:
RECRUITING
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Lead Sponsor:
Celgene
Conditions:
Neoplasms
Eligibility:
All Genders
Phase:
PHASE2
PHASE3
Brief Summary
This is a prospective study for the long-term follow-up (LTFU) of safety and efficacy for all pediatric and adult participants exposed to Gene-modified (GM) T-cell therapy participating in a previous ...
Eligibility Criteria
Inclusion
- Received at least one gene-modified (GM) T-cell infusion in a previous Celgene sponsored or Celgene alliance partner-sponsored trial, and have discontinued, or completed the post-treatment follow-up period in the parent treatment protocol, as applicable.
- Must understand and voluntarily sign an Informed Consent Form/Informed Assent Form prior to any study-related assessments/procedures being conducted.
Exclusion
- Not Applicable
- Other protocol-defined inclusion/exclusion criteria apply
Key Trial Info
Start Date :
July 19 2018
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
November 30 2036
Estimated Enrollment :
1541 Patients enrolled
Trial Details
Trial ID
NCT03435796
Start Date
July 19 2018
End Date
November 30 2036
Last Update
June 25 2025
Active Locations (182)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama Birmingham
Birmingham, Alabama, United States, 10016
2
Banner MD Anderson Cancer Center
Gilbert, Arizona, United States, 85234
3
Mayo Clinic Phoenix
Phoenix, Arizona, United States, 85054
4
Arizona Cancer Center
Scottsdale, Arizona, United States, 85258